What’s the outlook for Immutep shares in FY23?

A CSL scientist looking through a telescope in a labA CSL scientist looking through a telescope in a lab

Immutep Ltd (ASX: IMM) shares underperformed in FY22 as markets took a turn for the worse. Most of the previous year’s gains were erased.

However, the biotech company has caught a bid in July, as healthcare shares continue to strengthen in the new financial year.

The Immutep share price is flat today at 32.5 cents but it has gained 10% since the start of the month. Similarly, the S&P/ASX 200 Health Care Index (ASX: XHJ) is up 9% over the same period.

That is in stark contrast to June, when Immutep shares slumped by around 30%. They are now down 35% since this time last year.

What’s next for Immutep shares?

Immutep describes itself as a “biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases”.

After bouncing from lows of 29 cents on 30 June, Immutep shares have traded sideways and now rest at 32.5 cents apiece.

Earlier this month, the company announced it was granted a new patent (7074341) titled “AntiLAG-3 Antibodies” by the Japanese Patent Office.

The patent concerns the company’s drug candidate, IMP761. It covers all pharmaceutical formulas using IMP761 and “the use of the compositions in the treatment of T-cell mediated inflammatory and autoimmune diseases”.

“Immutep is well placed to make important contributions to this rapidly emerging field of immunotherapy — in both cancer and autoimmune diseases,” CEO Mark Voigt said.

The company also advised that its phase II TACTI-002 trial showed favourable results at readouts last month.

The study looked at combining Immutep’s lead drug candidate, efti, in combination with MSD’s pembrolizumab.

The trial met its primary objective, showing favourable anti-tumour activity. This data is now set to be presented at the 2022 IASLC 2022 World Conference on Lung Cancer, held on 6–9 August in Austria.

Meanwhile, Immutep shares are rated as a buy from 100% of the analysts covering the company, according to Refinitiv Eikon data.

From this list, the consensus price target is $1.18 per share, suggesting a mammoth 269% upside potential if these brokers are correct.

The post What’s the outlook for Immutep shares in FY23? appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);

More reading

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/u2s6WdV

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s